587

Supplementary materials 586

- Method and materials (continued) 588
- 589

590 Safety description

591 Overall, outcomes related to safety were assessed at any time point and included: any AEFIs, 592 any adverse events (AEs); serious, non-serious and leading to discontinuation, any adverse 593 events of special interest (AESIs), local injection site reactions, local reactions (e.g., erythema, 594 pain or swelling), systemic reactions (e.g. myalgia, rash, abdominal pain, itching, arthralgia, 595 muscle pain, chills, fatigue, fever, headache, nausea, vomiting or diarrhea), any related events, 596 any life-threatening related events, need for medical attention due to adverse reaction (e.g. 597 antipyretic or analgesic treatment, hospitalization, inability to perform daily activities or attend 598 school/work, telehealth consults, attendance to clinic or emergency room or taking medication 599 for side effects), serious adverse events (SAEs) (e.g. chest pain, tachycardia, dyspnea, 600 myocarditis, myopericarditis or severe allergic reactions), non-serious AEs, AEs leading to 601 discontinuation from the study, AEFI by system organ class (SOC) (e.g. infections and 602 infestations; general disorders and administration site conditions; nervous system disorders; 603 sleeping disturbancee; musculoskeletal and connective tissue disorders; respiratory, thoracic 604 and mediastinal disorders; cardiac disorders; arrhythmias; injury, poisoning and procedural 605 complications; vascular disorders; haemorrhagic diseases; thromboembolism; reproductive 606 system and breast disorders; hepato-renal syndrome; gastrointestinal disorders or psychiatric 607 disorders), unsolicited or unbalanced AEFIs (e.g. autoimmune diseases, Guillain-Barré 608 syndrome; acute aseptic arthritis or Bell's palsy), hypersensitivity, lymphadenopathy and 609 death. Then, we classified all adverse events as local and systemic AEFI, serious AEFI, AESI, 610 health impact, and unsolicited AEFI by SOC following any dose of BNT162b2 in adolescents 611

612 **Data extraction and management**

613 Study characteristics and outcomes data were extracted by a single reviewer and crosschecked 614 by a second reviewer to ensure consistency. Extractions were conducted using a pre-piloted 615 extraction form set up in Covidence, which included the following fields: (1) identification of 616 the study: country in which the study was conducted and time period over which the study was 617 conducted, (2) methods: aim of the study and study design, participants-mean age and age 618 group of participants included in the study, total number of participants included, number of participants per group (if reported), (3) interventions: follow-up period after vaccine administration (first and second dose), primary doses or booster administered and (4) safety outcomes: type of AEFI and number of events in each group and sub-age-group as well. (5) neutralising antibodies (type, titter and time) and (6) Level of efficacy of effectiveness (proportion and period of time after vaccination). At any point of time, discrepancies were resolved through consensus or adjudication by a senior review author. A Characteristics of included studies table was completed using descriptive information extracted from studies and exported into excel sheet from Covidence.

Supplementary tables and box

Outcome	Definition
Adverse event	An AEFI is any untoward medical occurrence which follows
following	immunization and which does not necessarily have a causal relationship with the
immunization (AEFI)	usage of the vaccine. The adverse event may be any unfavourable or unintended
	sign, abnormal laboratory finding, symptom or disease.
Serious adverse	A serious adverse event is any untoward medical occurrence that at any dose results
events (SAE)	in death, requires inpatient hospitalization or prolongation of existing
	hospitalization, results in persistent or significant disability/incapacity, or is life-
	threatening.
Solicited adverse	Solicited adverse events include prospectively self-collected occurrences of local
events	and systemic reactions. Participants were usually asked to monitor and record local
	reactions, systemic events, and antipyretic medication usage for 7 days following
	each administration.
Local reactions	Local reactions included pain at the injection site, redness, swelling, induration, etc.
Systemic reactions	Systemic reactions included headache, myalgia, fever, fatigue, vomiting, diarrhea, muscle pain, etc.
Unsolicited adverse	Unsolicited AEs would be represented in the AE domain unless they were classified
events	as solicited adverse event.
Adverse event of	An adverse event of special interest (serious or non-serious) is one of scientific and
special interest	medical concern specific to vaccine, for which ongoing monitoring can be
(AESI)	appropriate.
Withdrawal due to	The number of participants reported as withdrawn from clinical trial due to adverse
adverse events	events whether related to study intervention or not.
Death	The number of participants reported for death regardless of causality.

Supplementary Table 1: Definition of Safety Outcome (adapted from Wu et al)

Study ID, settings, design and average age of participants	Condition	Objective	Dose type	Outcomes of Interest	Event in immunoc ompromi sed	Total in immun ocompr omised	Event Control	Total Control	Time	Mean (SE) in AU/ml/Im munocomp romised	Total Immuno compro mised	Mean (SE) in Au/ml Control	Total Control	Authors conclusion
Akgun et al., 2022/Turkey, Prospective cohort of 15.4 ± 1.5 years	Rheumatic diseases	To examine vaccine antibody response of children and adolescents with rheumatic	Dose 1	Pain	24	41								Paediatric rheumatic diseases patients receiving immunomodulat ory treatments
		diseases in relation to confounding factors. To evaluate systemic		Swelling	2	41								were able to mount an effective humoral response after
		and local side effects of the BNT162b2 mRNA vaccine in		Erythema	1	41								two dose regimens of BNT162b2 mRNA vaccine
		children with paediatric rheumatic diseases.		Fever	5	41								safely without interrupting their current treatments.
		cibeabes.		Muscles aches	6	41								
				Headaches	10	41								
				Fatigue	13	41								
			Dose 2	Pain	20	41								
				Swelling	2	41]

635 Supplementary Table 2: Characteristic of included studies

				Erythema	1	41				
				Fever	6	41				
				Muscles aches	7	41				
				Headaches	11	41				
				Fatigue	12	41				
Bekenstein et al., 2022/Israel and Slovenia, Prospective cohort study, adolescents (12–	Rheumatic diseases	To explore safety and immunogenicity of the mRNA COVID-19 vaccine among	Dose 1	Pain	64	88				Evidence of good short-term vaccine safety and adequate humoral immune

18 years) and young adults		adolescents with juvenile-onset		Swelling	8	88								response in the unique
(18–21 years)		AIIRDs treated with		Erythema	2	88								population of adolescents with
		immunomodulato ry medications		Itching	3	88								juvenile-onset AIIRDs.
		and compared it with the results		Pruritus	1	88								
		among healthy children		Fever	14	88								
				Vomiting	2	88								
				Nausea	6	88								
				Running nose	4	88								
				Muscles	19	88								
				Joint pain	10	88								
				Chills	11	88								
				Headache	22	88								
				Feeling unwell	24	88								
				Weakness	25	88								
				Fatigue	29	88								
				Exacerbati on	1	88								
			Dose 2	Antibody seropositi vity	36	37	22	22	3 mont hs					
				IgG dosage					3 mont hs	93.07 (52.46)	37	149.15 (22.04)	22	
Dimopoulou et al., 2022/Greece, Single-center, cohort study of	Rheumatic diseases	To evaluate safety and tolerability of BNT162b2 COVID-19 vaccine in	Dose 2	Pain	21	42								mRNA vaccines appear to be safe and well tolerated in adolescents with
17 (16–21) years		adolescents		Swelling	12	42								JIA receiving treatment with
				Erythema	31	42								TNF inhibitors

				Muscles aches	5	42				
				Joint pain	5	42				
				Headache	7	42				
				Fatigue	6	42				
Haslak et al., 2021/Turkey, Cross-sectional study, of 15.34 (12.02-20.92)	Rheumatic diseases	To examine vaccine related adverse events of BNT162b2 messenger COVID-19	Dose 1	Fever	14	191				Acceptable safety profile of COVID-19 vaccines and encouragement of children with IRD to be
		vaccine		Vomiting	23	191				vaccinated.
				Nausea	2	191				
				Headache	10	191				
				Fatigue	25	191				
			Dose 2	Fever	12	191				
			2	Vomiting	6	191				
				Headache	14	191				
				Fatigue	19	191				
King et al., 2022/UK,	Neurodisa bilities	To inform the risk-benefit for	Dose 1	Erythema	1	26				Mild/moderate adverse
Prospective cohort of 12-15	Unities	subsequent COVID-19	1	Fever	3	26				reactions except for one child
years		vaccinations		Feeling unwell	10	26				
				Fatigue	19	26				
			Dose 2	Erythema	2	22				
			-	Fever	3	22				
				Feeling unwell	3	22				
				Fatigue	6	22				

Valentini et al., 2022/Italy, Prospective cohort of 17.90	Down syndrome	To evaluate the safety of mRNA vaccination in individuals with	Dose 1	Pain	10	40								Individuals with DS exhibit a good humoral response to the
(±4.59)		DS. To measured		Erythema	1	40								BNT162b2 vaccine;
		SARS-CoV-2 specific antibodies over		Fever	2	40								however, similarly to in HC, the immune
		time. To correlate		Muscles aches	1	40								response wanes over time.
		humoral immune response of		Chills	1	40								
		individuals with DS with those of		Headache	1	40								
		the healthy controls (HC)		Fatigue	1	40								
				Antibody seropositi vity	39	40	36	36						
			Dose 2	Pain	10									
				Erythema	2									
				Fever	4									
				Muscles aches	1									
				Headache	1									
				Fatigue	2									
			Dose 1	IgG dosage					21 days	14.29(7.68)	40	51.27(71.03)	36	
									28 days	1164.51(11 53.39)	40	2595.47(1273.9 2)	36	
								180 days	1100(153.7 8)	40	953.31(193.01)	36		
		Dose 2	IgG dosage					21 days	107.26(76. 89)	40	164.87(169.85)	36		
								28 days	107.26(76. 89)	40	800(30.88)	36		
									180 days	143.55(84. 58)	40	143.55(84.93)	36	

Michos et al., 2022/Italy, Prospective	Cystic fibrosis	To investigate immunogenicity of SARS-CoV-2	Dose 1	Antibody seropositi vity	27	33	38	66						BNT162b2 vaccine appears to be
cohort of 19.6 (17.6–24.3)		BNT162b2 vaccine and its association with epidemiological	Dose 2	Antibody seropositi vity	32	33	63	66	1 mont h					immunogenic with limited adverse events in CF
		and clinical parameters in a cohort of CF patients and to compare it with a cohort of healthy individuals	Dose 1	IgG dosage						222.45(116 2.05)	33	35.31(105.75)	66	population.
Piccini et al., 2022/Italy, Retrospective study, 18.4 ± 2.4	Type 1 diabetes	To evaluate adverse effects, possible glycemic control modification and	Dose 1	Pain	28	39								Vaccination not associated to significant perturbation of
		temporary insulin		Fever	5	39								glycemic control in adolescents
		dose adjustment in youth with T1D, users of		Muscles aches	5	39								and young adults with T1D, and, if elevation
		different levels of technology, who		Headache	7	39								of glucose values occurs, it
		completed a whole COVID-19		Weakness	16	39								is mild, transient,
		vaccination cycle	Dose 2	Pain	25	39								tolerable and not requiring insulin
			2	Fever	10									dose adjustment. Side effects are
				Muscles aches	5	39								mild and similar to those reported
				Headache	12	39								in the general population. All
				Weakness	17	39								in all, this information could be of clinical use when counseling families in order to reassure them about SARS- CoV-2 vaccination in youth with T1D.
Riviere et al., 2021/France, Retrospective	Solid tumour	To evaluate safety and efficacy of BNT162b2 vaccine in	Dose 1	Pain	6	13								Preliminary experience with RNA vaccines in AYA with

study, Median: 17 years	y	lolescents and young adults		Fever	2	13				solid tumours and report a
	(A	YA) with solid tumour.		Headache	1	13				good safety profile and
				Fatigue	2	13				excellent immunogenicity
			Dose 2	Pain	2	13				
				Fever	4	13				
				Vomiting	1	13				
			Fatigue	5	13					

638 Supplementary Table 3: Risk of bias in included studies (ROBINS-I)

Domain		Akgün 2022 (cohort)	Dimopoulou 2022 (cohort)	Haslak 2022 (cross- sectional)	Heshin-Bekenstein 2022 (controlled cohort)	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort)	Riviere 2021 (retrospective cohort)	Valentini 2022 (controlled cohort)
Bias due to confounding	Judgment Supporting text	Unclear Efficacy results are stratified by diagnoses and treatments. Safety results do not appear to be stratified.	Low Safety results are analysed by type of diagnosis and treatments.	Low Safety results are analysed by type of diagnosis, treatments, and other demographic characteristics.	High Efficacy results are stratified by treatments, no adjustment for confounders reported, however, age-matching was identified by authors as sub-optimal since controls were younger than participants with rheumatic disease. Safety results do not appear to be	Unclear Safety results are not stratified.	High Efficacy results are analysed by demographic and clinical characteristics, no adjustment for confounders reported. A lack of age and gender matching was reported by the authors. Safety results do not appear to be stratified or adjusted.	Unclear Safety results are not stratified.	Unclear Efficacy and safety results are not stratified.	High Efficacy results are analysed by demographic and clinical characteristics, no adjustment for confounders reported. Authors identified the lack of age-matched controls as a limitation. Safety results do not appear to be stratified or adjusted.
Bias in	Judgment	Unclear	Unclear	Unclear	stratified or adjusted for confounders. Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
selection of participants into the study	Supporting text	Patients were invited by phone call – it is unclear	Insufficient information on	Data were captured by web-based	Insufficient information on recruitment of	Clinician- identified patients were invited	Insufficient information on recruitment of	Insufficient information on inclusion into	Insufficient information on recruitment.	Insufficient information on recruitment of

Domain		Akgün 2022 (cohort) whether	Dimopoulou 2022 (cohort)	Haslak 2022 (cross- sectional)	Heshin-Bekenstein 2022 (controlled cohort) patients with	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort) this	Riviere 2021 (retrospective cohort) Informed	Valentini 2022 (controlled cohort) patients with Down
		volunteer bias may be present.	recruitment. Informed consent was sought, volunteer bias could not be ruled out.	survey, with no information on recruitment – it is unclear whether volunteer bias may be present.	patients with rheumatic disease as well as healthy controls. These groups were recruited from different centres. Informed consent was sought.	following informed medical consent. It is unclear whether volunteer bias may be present.	patients with cystic fibrosis as well as healthy controls. These groups were systematically different as controls were healthcare workers. Informed consent was sought.	retrospective study.	consent was sought, volunteer bias could not be ruled out.	patients with Down syndrome as well as healthy controls. These groups were systematically different as controls were healthcare workers. Informed consent was sought.
Bias in	Judgment	Low	Low	Unclear	Low	Low	Unclear	Unclear	Low	Unclear
classification of interventions	Supporting text	Patients were vaccinated with the BNT162b2 mRNA vaccine post-recruitment.	Patients were vaccinated with the BNT162b2 mRNA vaccine post- recruitment.	Vaccination status was verified by phone calls and national registries, however, two types of COVID-19 vaccine was available. It is not clear how the type of vaccine received was determined.	Patients were vaccinated with the BNT162b2 mRNA vaccine post- recruitment.	Patients were vaccinated with the BNT162b2 mRNA vaccine post-recruitment.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post- recruitment, or whether vaccination status was confirmed.	It is not reported how vaccination status was verified.	Patients were vaccinated with the BNT162b2 mRNA vaccine post- recruitment.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post- recruitment, or whether vaccination status was confirmed.
Bias due to	Judgment	Unclear	Unclear	Low	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
deviations from intended interventions	Supporting text	It is not reported whether – or how - vaccination status of participants was determined.	It is not reported how vaccination status of participants was determined.	Vaccination status was verified by phone calls and national registries.	It is not reported whether – or how - vaccination status of participants was determined.	It is not reported whether – or how - vaccination status of participants was determined.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post- recruitment, or whether vaccination status was confirmed.	It is not reported how vaccination status of participants was determined.	It is not reported whether – or how - vaccination status of participants was determined.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post- recruitment, or whether vaccination status was confirmed.
Bias due to	Judgment	Unclear	Unclear	Low	High	Unclear	Unclear	Unclear	Low	Low
missing data	Supporting text	No withdrawals or loss to follow up is reported, but some investigator- driven exclusions, e.g. exclusion of patients without complete	No details on how many participants were potentially eligible, therefore attrition could not be assessed.	A total of 39/285 potentially eligible patients (14%) were excluded, but with reasons that were considered reasonable.	Approximately 3% loss to follow-up in the group with rheumatic disease following the second dose, with no loss to follow-up in the control group. High attrition for/low availability of	No details on how many participants were potentially eligible, therefore attrition could not be assessed.	No withdrawals or loss to follow up is reported, but some investigator-driven exclusions are implied, e.g. exclusion of patients without full vaccination. This does not align with	No withdrawals or loss to follow up is reported, but some investigator- driven exclusions are implied, e.g. inclusion of only patients	Approximately 23% loss to follow-up, but for valid reasons, and no investigator- driven exclusions are reported.	No withdrawals or loss to follow up is reported and investigator-driven exclusion of individuals with Down syndrome, for the presence of antibodies at baseline, is

Domain		Akgün 2022 (cohort)	Dimopoulou 2022 (cohort)	Haslak 2022 (cross- sectional)	Heshin-Bekenstein 2022 (controlled cohort)	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort)	Riviere 2021 (retrospective cohort)	Valentini 2022 (controlled cohort)
		vaccination schedule (14% of total sample), do not align with the review question.			immunogenicity data (41% in rheumatic disease group and 55% in the control group provided data) due to limited availability of serum samples. No further exclusions reported.		the review question, though its impact could not be numerically assessed.	who underwent a whole vaccination cycle. This does not align with the review question, though its impact could not be numerically assessed.		considered reasonable.
Bias in	Judgment	Unclear	Unclear	Unclear	High	Unclear	Unclear	Unclear	Unclear	Unclear
measurement of outcomes	Supporting text	Efficacy outcomes were clearly defined and laboratory- determined, with minimal risk of ascertainment bias. Safety outcomes were participant- reported, using a structured questionnaire; while this may have introduced bias this would not be differential, given the single-arm design.	Safety outcomes were participant- recorded, using a diary card; while this may have introduced bias this would not be differential, given the single-arm design.	It is not clear whether safety assessed: 'experienced adverse events of the participants were verified by phone calls and national registries.'	Efficacy outcomes were clearly defined and laboratory- determined, with minimal risk of ascertainment bias. Safety outcomes, however, were participant-reported using a telephonic questionnaire. Given the controlled nature of the study, this may have biased measures of association.	Parents were asked to record side effects in a diary and were followed up with a telephone call; while this may have introduced bias this would not be differential, given the single- arm design.	Efficacy outcomes were clearly defined and laboratory- determined, with minimal risk of ascertainment bias. Safety outcomes were participant- reported; while this may have introduced bias this would not be differential, given the single-arm safety comparison.	Symptoms after first and second dose recorded in medical files were retrospectively investigated, either face to face or via telemedicine.	Efficacy outcomes were clearly defined and laboratory- determined, with minimal risk of ascertainment bias. Safety outcomes were participant- reported; while this may have introduced bias this would not be differential, given the single-arm design.	Efficacy outcomes were clearly defined and laboratory- determined, with minimal risk of ascertainment bias. Safety outcomes were participant- reported; while this may have introduced bias this would not be differential, given the single-arm safety comparison.
Bias in	Judgment	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
selection of the reported result	Supporting text	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.
Other source	Judgment	Unclear	Low	Unclear	Unclear	Low	Unclear	Low	Unclear	Unclear
of bias	Supporting text	Lack of control group, small sample size, short	None identified.	Details on medication doses, duration of treatment and	Disease diversity limited conclusions regarding the effect of	None identified.	Limited numbers of patients with cystic fibrosis.	None identified.	Small sample size, patients were limited to those with solid	Small sample size.

Domain		Akgün 2022 (cohort)	Dimopoulou 2022 (cohort)	Haslak 2022 (cross- sectional)	Heshin-Bekenstein 2022 (controlled cohort)	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort)	Riviere 2021 (retrospective cohort)	Valentini 2022 (controlled cohort)
		post-vaccine follow-up.		disease activity not available. Some groups with vaccine effect- modifying characteristics were grouped together.	immunomodulatory medication and disease type on efficacy.				tumours limiting generalisability to all paediatric oncology patients, short post-vaccine follow-up.	
Overall bias	Judgment	Unclear	Unclear	Unclear	High	Unclear	High	Unclear	Unclear	High
	Supporting text	Bias due to confounding and deviations from intended interventions as well as selection bias, attrition bias, ascertainment bias and selective outcome reporting could not be ruled out. Several other limitations were identified.	Bias due to deviations from intended interventions as well as selection bias, attrition bias, attrition bias and selective outcome reporting could not be ruled out.	Selection bias, classification bias, ascertainment bias, and selective outcome reporting could not be ruled out. Several other limitations were identified.	High risk of confounding, attrition bias and ascertainment bias. Bias due to deviations from intended interventions as well as selection bias and selective outcome reporting could not be ruled out. Several other limitations were identified.	Bias due to confounding and deviations from intended interventions as well as selection bias, attrition bias, ascertainment bias and selective outcome reporting could not be ruled out.	High risk of confounding. Selection bias, classification bias, deviation from intended interventions, attrition bias, ascertainment bias, and selective outcome reporting could not be ruled out. Other limitations were also identified.	Confounding, selection bias, classification bias, deviation from intended interventions, attrition bias, ascertainment bias, and selective outcome reporting could not be ruled out.	Confounding, selection bias, deviation from intended interventions, ascertainment bias, and selective outcome reporting could not be ruled out. Several other limitations were identified.	High risk of confounding. Selection bias, classification bias, deviation from intended interventions, ascertainment bias, and selective outcome reporting could not be ruled out. Other limitations were also identified.

Supplementary box 1: Search terms built for MEDLINE (PubMed) ("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh] OR "COVID-19 Vaccines"[Mesh] OR "COVID-19 Serological Testing"[Mesh] OR "COVID-19 Nucleic Acid Testing"[Mesh] OR "SARS-CoV-2 variants" [Supplementary Concept] OR "COVID-19 drug treatment" [Supplementary Concept] OR "COVID-19 serotherapy" [Supplementary Concept] OR "2019-nCoV" OR "2019nCoV" OR "cov 2" OR "Covid-19" OR "sars coronavirus 2" OR "sars cov 2" OR "SARS-CoV-2" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus 2" OR "COVID 19" OR "COVID-19" OR "2019 ncov" OR "2019nCoV" OR "corona virus disease 2019" OR "cov2" OR "COVID-19" OR "COVID19" OR "nCov 2019" OR "nCoV" OR "new corona virus" OR "new coronaviruses" OR "novel corona virus" OR "novel coronaviruses" OR "SARS Coronavirus 2" OR "SARS2" OR "SARS-COV-2" OR "Severe Acute Respiratory Syndrome Coronavirus 2") AND (BNT162b2[All Fields] OR Pfizer-BioNTech[All Fields] OR Pfizer/BioNTech[All Fields] OR Comirnaty[All Fields]) AND (tolerability[Title/Abstract] OR reactogenicity[Title/Abstract] OR safe*[Title/Abstract] OR side effect[Title/Abstract] OR adverse event[Title/Abstract] OR adverse effect[Title/Abstract] OR adverse reaction[Title/Abstract] OR adverse OR efficacy[Title/Abstract] OR effectiveness[Title/Abstract] OR outcome[Title/Abstract] OR undesirable effect*[Title/Abstract] OR treatment emergent[Title/Abstract] OR toxicity[Title/Abstract]) AND ("Adolescent" [Mesh] OR "Adolescent" [Title/Abstract] OR "Teent" [Title/Abstract] OR "Youtht" [Title/Abstract] OR "juvenilet" [Title/Abstract] OR "puberty" [Title/Abstract] OR "young*" [Title/Abstract] OR "Child" [Mesh] OR "child*" [Title/Abstract] OR "Pediatrics" [Mesh])

642

643

644

645